Sign In
Buy XCUR
$2.74
+0.430 (+18.61%)
At Close: Jun 22, 2026
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
04:01pm, Wednesday, 10'th Jun 2026
WILMINGTON, Del. , June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of T
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
04:01pm, Wednesday, 10'th Jun 2026
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department o
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
04:00pm, Monday, 01'st Jun 2026
Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
07:54pm, Wednesday, 22'nd Apr 2026
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co. , Ltd. (KOSDAQ: 179530), a Korea-based b
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
07:54pm, Wednesday, 22'nd Apr 2026
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based bi
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
04:01pm, Thursday, 02'nd Apr 2026
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the follo
Exicure, Inc. Reports Full Year 2025 Financial Results
04:18pm, Wednesday, 25'th Mar 2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
07:00am, Wednesday, 21'st Jan 2026
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it w
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December
03:44am, Thursday, 15'th Jan 2026
Exicure, Inc. (NASDAQ: XCUR - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,368 sha
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial
11:39am, Tuesday, 09'th Dec 2025
Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.
This BlackRock stock just rocketed 70%
09:32am, Tuesday, 09'th Dec 2025
Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged a massive rally as investors reacted to the company's new br
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
04:30pm, Monday, 08'th Dec 2025
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive
Exicure, Inc. Reports Third Quarter 2025 Financial Results
04:00pm, Friday, 07'th Nov 2025
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025.
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
09:00am, Monday, 03'rd Nov 2025
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that resu
